<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02078635</url>
  </required_header>
  <id_info>
    <org_study_id>REB 13-260</org_study_id>
    <secondary_id>FRN 129920</secondary_id>
    <nct_id>NCT02078635</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Imaging-Portfolio Diet Study #7</brief_title>
  <acronym>MRIPD#7</acronym>
  <official_title>The Canada-wide Human Nutrition Trialists' Network</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Presently in Canada, 29% of deaths are due to cardiovascular disease (CVD), costing $20.9
      billion annually. The investigators have, therefore, brought together an unique network of
      investigators at different stages in their careers with a range of disciplines (nutrition,
      cardiology, diabetes, imaging, physics, clinical trials, statistics, laboratory medicine,
      primary care, genetics, psychology, knowledge translation (KT), and epidemiology) and with
      international recognition , experience and connections, to undertake a multi-centre study
      which will test the ability of the dietary Portfolio PLUS approach over 3 years to reduce the
      progression of plaque build-up in the carotid artery as assessed by Magnetic Resonance
      Imaging (MRI) in individuals with hypercholesterolemia.

      The dietary portfolio of cholesterol-lowering foods (viscous fibres, soy protein, plant
      sterol and nuts) which has been proven in many of their studies to be an effective
      cholesterol-lowering diet will be further enhanced by increased levels of monounsaturated
      fats (MUFA) and low glycemic index foods. Will this enhanced dietary strategy (dietary
      Portfolio PLUS ) reduce the progression of carotid atheromatous lesions, LDL-C and blood
      pressure while reducing the number of hyperlipidemic individuals requiring statins?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As Western populations age and as body weight increases, the need for dietary strategies to
      reduce Coronary Heart Disease (CHD) risk continues. The investigators are now in a position
      to put together a dietary approach which will be a significant advance over current dietary
      advice for CHD risk reduction. The investigators believe this study using imaging and
      functional techniques is now needed to 1) demonstrate an improvement in estimated CHD risk
      based on anatomical changes rather than serum risk factors. 2) encourage popular uptake and
      clinical use of this combination dietary strategy and 3) stimulate a larger longer term trial
      with CHD events.

      Participants for this study will be recruited in 4 academic centres across Canada (Quebec,
      Toronto, Winnipeg and Vancouver). They will be in the low or moderate risk category based on
      the current Canadian Cardiovascular Society's (CCS) Guidelines 2012 and would normally be
      considered for initial treatment with lifestyle only. All participants will first be screened
      by ultrasound for the presence of plaque in the carotid arteries and will then be randomized
      to one of the 2 treatment arms: Portfolio Plus diet (test) or modified DASH diet (control),
      both given as routine clinical advice with follow up visits at 3-month intervals for 6 months
      and then twice yearly for the remainder of the 3 year trial.

      Prior to starting either diet, participants will undergo screening ultrasound examination of
      both right and left carotids to enable selection of those individuals whose intima-media
      thickness would be 5-30% below the cut point considered by the Mannheim Consensus as relevant
      arterial thickening to ensure a relatively low risk group, yet with some measurable arterial
      thickening. The main outcome will be MRI assessment of maximum vessel wall volume. This
      assessment will be repeated at year 3. It will be emphasized at the outset that both the
      dietary portfolio and the DASH-like diets have been associated with benefits in terms of
      cholesterol reduction to provide equal encouragement for those randomized to the test and
      control groups. Portfolio and DASH-like dietary advice will consist of half hour individual
      sessions with the dietitian at baseline, 3, and 6 months and then at 6-month intervals. Prior
      to starting each diet, instruction will be given on achieving the dietary goals.

      At follow-up visits, the participants' completed 7-day diet records will be discussed and the
      original advice reinforced. Every effort will be made to obtain study blood samples and
      carotid imaging data from all subjects at the designated times regardless of adherence to the
      dietary aspects of the study protocol. All subjects will be included in the
      intention-to-treat analysis.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was amalgamated with another study to include exercise as another intervention.
  </why_stopped>
  <completion_date type="Actual">October 7, 2014</completion_date>
  <primary_completion_date type="Actual">October 7, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of the maximum vessel wall volume of the carotid arteries</measure>
    <time_frame>At baseline and year 3</time_frame>
    <description>Assessed by MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra-plaque hemorrhage (IPH)</measure>
    <time_frame>At baseline and year 3</time_frame>
    <description>Assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-plaque lipid (lipid-rich necrotic core)</measure>
    <time_frame>baseline and year 3</time_frame>
    <description>Assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure and pulse rate</measure>
    <time_frame>At months 0, 3, 6, 12, 18, 24, 30, 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>initiation of statin therapy</measure>
    <time_frame>baseline and year 3</time_frame>
    <description>According to current CCS guidelines</description>
  </secondary_outcome>
  <other_outcome>
    <measure>LDL-cholesterol</measure>
    <time_frame>At months, 0, 3, 6, 12, 18, 24, 30, 36</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>HDL-cholesterol</measure>
    <time_frame>months 0, 3, 6, 12, 18, 24, 30, 36</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>At months 0, 12, 24, and 36</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Medical Outcomes Study 36-Item Short Form Questionnaire (SF-36)</measure>
    <time_frame>Months 0 and 36</time_frame>
    <description>Survey on quality of life.</description>
  </other_outcome>
  <other_outcome>
    <measure>Genetic whole genome testing</measure>
    <time_frame>month 0</time_frame>
    <description>One time sample collection of buffy coat white cells for future analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>satiety of the test and control diet</measure>
    <time_frame>Months 0, 3, 6, 12, 18, 24, 30, 36</time_frame>
    <description>Participants will assess their level of satiety on the test/control diet at each visit using a 9-point bipolar semantic scale ranging from -4 (being starved/ feeling weak and faint with hunger) to +4 (being Painfully full) with 0 being neutral (ie don't mind eating a little more or less).</description>
  </other_outcome>
  <other_outcome>
    <measure>Palatability of the test / control diets</measure>
    <time_frame>Months 3, 6, 12, 18, 24, 30, and 36</time_frame>
    <description>The palatability of the diet will by measured using a numerical scale of 1 to 10 (1= strongly dislike and 10 = like very much).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Diabetes</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Portfolio Plus Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be advised to follow a low glycemic index dietary portfolio. Specifically, the advice will be to limit saturated fat (to &lt;7% of total calories and cholesterol to &lt;200 mg/d) plus inclusion of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat and selection of low glycemic index foods; emphasizing current recommendations for fruit and vegetable intakes (5-10 servings/d)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DASH-like (high fibre) diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The DASH-like dietary advice will emphasize a diet of whole grains, low-fat dairy and current recommendations for fruit and vegetables (5-10 servings/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Portfolio Plus Diet</intervention_name>
    <description>Foods on the Portfolio Plus plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran bread and soups) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese) and additional sources of plant proteins from pulses (eg. lentils, chickpeas, beans, etc); and 22.5 g almonds or equivalent of other nuts/1000 kcal and increase MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale)</description>
    <arm_group_label>Portfolio Plus Diet</arm_group_label>
    <other_name>Dietary Portfolio of cholesterol-lowering foods</other_name>
    <other_name>Enhanced portfolio</other_name>
    <other_name>Portfolio eating plan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>DASH-like (high fibre) dietary advice</intervention_name>
    <description>Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce red meat consumption, choose low fat dairy foods and a control margarine</description>
    <arm_group_label>DASH-like (high fibre) diet</arm_group_label>
    <other_name>high fibre diet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Eligible participants will be:

          1. Adult males that are within 30% of their target LDL-cholesterol for the low or
             moderate risk category according to the 2012 Canadian Cardiovascular Society
             Guidelines.

          2. Postmenopausal women that are within 30% of their target LDL-cholesterol for the low
             or moderate risk category according to the 2012 Canadian Cardiovascular Society
             Guidelines.

        Participants will have the following characteristics:

          -  BMI 25-40 kg/m2 with body weight that has remained constant (within ±2kg) over the
             last 3 months preceding the onset of the study.

          -  Measurable arterial thickening at screening (carotid intima-media thickness of &gt;1.0mm)

          -  Plus at least 1 of the following 3 criteria:

               -  are treated with statins

               -  are statin intolerant

               -  have refused statin treatment after consultation with the appropriate physician

        Exclusion Criteria:

        Individuals with the following conditions will be excluded:

          -  major cardiovascular event

               -  stroke or

               -  myocardial infarction

          -  Cardiac conditions that compromise normal function

               -  mitral valve disease

               -  heart failure

               -  angina

          -  familial hypercholesterolemia

          -  secondary causes of hypercholesterolemia

               -  hypothyroidism (unless treated and on a stable dose of L-thyroxine)

               -  renal or liver disease

          -  diabetes

          -  serum triglycerides &gt;4.5 mmol/L

          -  uncontrolled blood pressure

          -  major disability

          -  disorders requiring continuous medical attention and treatment

               -  chronic heart failure

               -  liver disease

               -  renal failure

               -  cancer (except non-melanoma skin cancer--basal cell, squamous cell)

          -  chronic infections (bacterial or viral)

          -  chronic inflammatory diseases ( lupus, ulcerative colitis)

          -  other autoimmune diseases (eg celiac disease or gluten sensitivity)

          -  major surgery &lt;6 months prior to randomization

          -  conditions that make them unsuitable for MRI (e.g. have metal implants or are
             claustrophobic)

          -  alcohol consumption &gt;2 drinks/ day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Jenkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital / University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benoit Lamarche, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Jones, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiri Frohlich, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Healthy Heart Lipid Clinic, St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richardson Center for Functional Foods and Nutraceuticals and the St. Boniface Hospital Cardiovascular Center, University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3T 6C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Risk Factor Modification Centre, St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Nutraceuticals and Functional Foods and the Quebec Heart and Lung Institute, Laval University</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Jenkins DJ, Jones PJ, Lamarche B, Kendall CW, Faulkner D, Cermakova L, Gigleux I, Ramprasath V, de Souza R, Ireland C, Patel D, Srichaikul K, Abdulnour S, Bashyam B, Collier C, Hoshizaki S, Josse RG, Leiter LA, Connelly PW, Frohlich J. Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial. JAMA. 2011 Aug 24;306(8):831-9. doi: 10.1001/jama.2011.1202.</citation>
    <PMID>21862744</PMID>
  </reference>
  <reference>
    <citation>Statistics Canada. Mortality, Summary list of Causes 2008. Released October 18, 2011</citation>
  </reference>
  <reference>
    <citation>Conference Board of Canada. The Canadian Heart Healthy Strategy: Risk Factors and Future Cost Implications. Report of February 2010.</citation>
  </reference>
  <reference>
    <citation>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97.</citation>
    <PMID>11368702</PMID>
  </reference>
  <reference>
    <citation>Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman JW Jr, Kris-Etherton P, Goldberg IJ, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson K, Wylie-Rosett J, St Jeor S, Suttie J, Tribble DL, Bazzarre TL. AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation. 2000 Oct 31;102(18):2284-99.</citation>
    <PMID>11056107</PMID>
  </reference>
  <reference>
    <citation>Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol. 2009 Oct;25(10):567-79. Review.</citation>
    <PMID>19812802</PMID>
  </reference>
  <reference>
    <citation>Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990 Jul 21;336(8708):129-33.</citation>
    <PMID>1973470</PMID>
  </reference>
  <reference>
    <citation>Atkins R. Dr. Atkins' New Diet Revolution. New York NAB.</citation>
  </reference>
  <reference>
    <citation>Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998 Dec 16;280(23):2001-7. Erratum in: JAMA 1999 Apr 21;281(15):1380.</citation>
    <PMID>9863851</PMID>
  </reference>
  <reference>
    <citation>Jenkins DJ, Chiavaroli L, Wong JM, Kendall C, Lewis GF, Vidgen E, Connelly PW, Leiter LA, Josse RG, Lamarche B. Adding monounsaturated fatty acids to a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. CMAJ. 2010 Dec 14;182(18):1961-7. doi: 10.1503/cmaj.092128. Epub 2010 Nov 1.</citation>
    <PMID>21041432</PMID>
  </reference>
  <reference>
    <citation>Food labeling: health claims; plant sterol/stanol esters and coronary heart disease. Food and Drug Administration, HHS. Interim final rule. Fed Regist. 2000 Sep 8;65(175):54686-739.</citation>
    <PMID>11503640</PMID>
  </reference>
  <reference>
    <citation>Jenkins DJ, Kendall CW, McKeown-Eyssen G, Josse RG, Silverberg J, Booth GL, Vidgen E, Josse AR, Nguyen TH, Corrigan S, Banach MS, Ares S, Mitchell S, Emam A, Augustin LS, Parker TL, Leiter LA. Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. JAMA. 2008 Dec 17;300(23):2742-53. doi: 10.1001/jama.2008.808.</citation>
    <PMID>19088352</PMID>
  </reference>
  <reference>
    <citation>Jenkins DJ, Kendall CW, Augustin LS, Mitchell S, Sahye-Pudaruth S, Blanco Mejia S, Chiavaroli L, Mirrahimi A, Ireland C, Bashyam B, Vidgen E, de Souza RJ, Sievenpiper JL, Coveney J, Leiter LA, Josse RG. Effect of legumes as part of a low glycemic index diet on glycemic control and cardiovascular risk factors in type 2 diabetes mellitus: a randomized controlled trial. Arch Intern Med. 2012 Nov 26;172(21):1653-60.</citation>
    <PMID>23089999</PMID>
  </reference>
  <reference>
    <citation>Jones PJ, AbuMweis SS. Phytosterols as functional food ingredients: linkages to cardiovascular disease and cancer. Curr Opin Clin Nutr Metab Care. 2009 Mar;12(2):147-51. Review.</citation>
    <PMID>19209468</PMID>
  </reference>
  <reference>
    <citation>Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R, Emam A, Parker TL, Vidgen E, Lapsley KG, Trautwein EA, Josse RG, Leiter LA, Connelly PW. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA. 2003 Jul 23;290(4):502-10.</citation>
    <PMID>12876093</PMID>
  </reference>
  <reference>
    <citation>Jenkins DJ, Kendall CW, Faulkner D, Vidgen E, Trautwein EA, Parker TL, Marchie A, Koumbridis G, Lapsley KG, Josse RG, Leiter LA, Connelly PW. A dietary portfolio approach to cholesterol reduction: combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. Metabolism. 2002 Dec;51(12):1596-604.</citation>
    <PMID>12489074</PMID>
  </reference>
  <reference>
    <citation>Jenkins DJ, Kendall CW, Marchie A, Faulkner D, Vidgen E, Lapsley KG, Trautwein EA, Parker TL, Josse RG, Leiter LA, Connelly PW. The effect of combining plant sterols, soy protein, viscous fibers, and almonds in treating hypercholesterolemia. Metabolism. 2003 Nov;52(11):1478-83.</citation>
    <PMID>14624410</PMID>
  </reference>
  <reference>
    <citation>Jenkins DJ, Wolever TM, Taylor RH, Barker H, Fielden H, Baldwin JM, Bowling AC, Newman HC, Jenkins AL, Goff DV. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981 Mar;34(3):362-6.</citation>
    <PMID>6259925</PMID>
  </reference>
  <reference>
    <citation>Hu FB, Stampfer MJ, Manson JE, Rimm EB, Colditz GA, Rosner BA, Speizer FE, Hennekens CH, Willett WC. Frequent nut consumption and risk of coronary heart disease in women: prospective cohort study. BMJ. 1998 Nov 14;317(7169):1341-5.</citation>
    <PMID>9812929</PMID>
  </reference>
  <reference>
    <citation>Liu S, Willett WC, Stampfer MJ, Hu FB, Franz M, Sampson L, Hennekens CH, Manson JE. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr. 2000 Jun;71(6):1455-61.</citation>
    <PMID>10837285</PMID>
  </reference>
  <reference>
    <citation>Pereira MA, O'Reilly E, Augustsson K, Fraser GE, Goldbourt U, Heitmann BL, Hallmans G, Knekt P, Liu S, Pietinen P, Spiegelman D, Stevens J, Virtamo J, Willett WC, Ascherio A. Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies. Arch Intern Med. 2004 Feb 23;164(4):370-6.</citation>
    <PMID>14980987</PMID>
  </reference>
  <reference>
    <citation>Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003 May;77(5):1146-55.</citation>
    <PMID>12716665</PMID>
  </reference>
  <reference>
    <citation>Keys A, Aravanis C, Blackburn HW, Van Buchem FS, Buzina R, Djordjević BD, Dontas AS, Fidanza F, Karvonen MJ, Kimura N, Lekos D, Monti M, Puddu V, Taylor HL. Epidemiological studies related to coronary heart disease: characteristics of men aged 40-59 in seven countries. Acta Med Scand Suppl. 1966;460:1-392.</citation>
    <PMID>5226858</PMID>
  </reference>
  <reference>
    <citation>Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, Golan R, Fraser D, Bolotin A, Vardi H, Tangi-Rozental O, Zuk-Ramot R, Sarusi B, Brickner D, Schwartz Z, Sheiner E, Marko R, Katorza E, Thiery J, Fiedler GM, Blüher M, Stumvoll M, Stampfer MJ; Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008 Jul 17;359(3):229-41. doi: 10.1056/NEJMoa0708681. Erratum in: N Engl J Med. 2009 Dec 31;361(27):2681.</citation>
    <PMID>18635428</PMID>
  </reference>
  <reference>
    <citation>Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Desvarieux M, Ebrahim S, Fatar M, Hernandez Hernandez R, Kownator S, Prati P, Rundek T, Taylor A, Bornstein N, Csiba L, Vicaut E, Woo KS, Zannad F; Advisory Board of the 3rd Watching the Risk Symposium 2004, 13th European Stroke Conference. Mannheim intima-media thickness consensus. Cerebrovasc Dis. 2004;18(4):346-9. Epub 2004 Nov 2. Review.</citation>
    <PMID>15523176</PMID>
  </reference>
  <reference>
    <citation>Jenkins DJ, Kendall CW, Faulkner DA, Nguyen T, Kemp T, Marchie A, Wong JM, de Souza R, Emam A, Vidgen E, Trautwein EA, Lapsley KG, Holmes C, Josse RG, Leiter LA, Connelly PW, Singer W. Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. Am J Clin Nutr. 2006 Mar;83(3):582-91.</citation>
    <PMID>16522904</PMID>
  </reference>
  <reference>
    <citation>The DASH diet. Dietary Approaches to Stop Hypertension. Lippincotts Prim Care Pract. 1998 Sep-Oct;2(5):536-8.</citation>
    <PMID>9791393</PMID>
  </reference>
  <reference>
    <citation>Murie-Fernandez M, Irimia P, Toledo E, Martínez-Vila E, Buil-Cosiales P, Serrano-Martínez M, Ruiz-Gutiérrez V, Ros E, Estruch R, Martínez-González MÁ; PREDIMED Investigators. Carotid intima-media thickness changes with Mediterranean diet: a randomized trial (PREDIMED-Navarra). Atherosclerosis. 2011 Nov;219(1):158-62. doi: 10.1016/j.atherosclerosis.2011.06.050. Epub 2011 Jul 6.</citation>
    <PMID>21802081</PMID>
  </reference>
  <reference>
    <citation>Black AE, Goldberg GR, Jebb SA, Livingstone MB, Cole TJ, Prentice AM. Critical evaluation of energy intake data using fundamental principles of energy physiology: 2. Evaluating the results of published surveys. Eur J Clin Nutr. 1991 Dec;45(12):583-99. Review.</citation>
    <PMID>1810720</PMID>
  </reference>
  <reference>
    <citation>Bingham SA, Gill C, Welch A, Day K, Cassidy A, Khaw KT, Sneyd MJ, Key TJ, Roe L, Day NE. Comparison of dietary assessment methods in nutritional epidemiology: weighed records v. 24 h recalls, food-frequency questionnaires and estimated-diet records. Br J Nutr. 1994 Oct;72(4):619-43.</citation>
    <PMID>7986792</PMID>
  </reference>
  <reference>
    <citation>Composition of Foods, Agriculture Handbook No. 8. In: Agriculture UDo, ed.: The Agriculture Research Service, 1992.</citation>
  </reference>
  <reference>
    <citation>Smilde TJ, van Wissen S, Wollersheim H, Kastelein JJ, Stalenhoef AF. Genetic and metabolic factors predicting risk of cardiovascular disease in familial hypercholesterolemia. Neth J Med. 2001 Oct;59(4):184-95. Review.</citation>
    <PMID>11578794</PMID>
  </reference>
  <reference>
    <citation>van Wissen S, Smilde TJ, Trip MD, Stalenhoef AF, Kastelein JJ. Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol. 2005 Jan 15;95(2):264-6.</citation>
    <PMID>15642565</PMID>
  </reference>
  <reference>
    <citation>Johnsen SH, Mathiesen EB, Joakimsen O, Stensland E, Wilsgaard T, Løchen ML, Njølstad I, Arnesen E. Carotid atherosclerosis is a stronger predictor of myocardial infarction in women than in men: a 6-year follow-up study of 6226 persons: the Tromsø Study. Stroke. 2007 Nov;38(11):2873-80. Epub 2007 Sep 27.</citation>
    <PMID>17901390</PMID>
  </reference>
  <reference>
    <citation>Mathiesen EB, Johnsen SH, Wilsgaard T, Bønaa KH, Løchen ML, Njølstad I. Carotid plaque area and intima-media thickness in prediction of first-ever ischemic stroke: a 10-year follow-up of 6584 men and women: the Tromsø Study. Stroke. 2011 Apr;42(4):972-8. doi: 10.1161/STROKEAHA.110.589754. Epub 2011 Feb 10.</citation>
    <PMID>21311059</PMID>
  </reference>
  <reference>
    <citation>Spence JD. Technology Insight: ultrasound measurement of carotid plaque--patient management, genetic research, and therapy evaluation. Nat Clin Pract Neurol. 2006 Nov;2(11):611-9. Review.</citation>
    <PMID>17057748</PMID>
  </reference>
  <reference>
    <citation>Saam T, Kerwin WS, Chu B, Cai J, Kampschulte A, Hatsukami TS, Zhao XQ, Polissar NL, Neradilek B, Yarnykh VL, Flemming K, Huston J 3rd, Insull W Jr, Morrisett JD, Rand SD, DeMarco KJ, Yuan C. Sample size calculation for clinical trials using magnetic resonance imaging for the quantitative assessment of carotid atherosclerosis. J Cardiovasc Magn Reson. 2005;7(5):799-808.</citation>
    <PMID>16353440</PMID>
  </reference>
  <reference>
    <citation>Lee GA. Determinants of quality of life five years after coronary artery bypass graft surgery. Heart Lung. 2009 Mar-Apr;38(2):91-9. doi: 10.1016/j.hrtlng.2008.04.003. Epub 2008 Sep 19.</citation>
    <PMID>19254627</PMID>
  </reference>
  <reference>
    <citation>Pischke CR, Weidner G, Elliott-Eller M, Ornish D. Lifestyle changes and clinical profile in coronary heart disease patients with an ejection fraction of &lt;or=40% or &gt;40% in the Multicenter Lifestyle Demonstration Project. Eur J Heart Fail. 2007 Sep;9(9):928-34. Epub 2007 Jun 14.</citation>
    <PMID>17572148</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arterial plaque</keyword>
  <keyword>portfolio diet</keyword>
  <keyword>dietary modification</keyword>
  <keyword>dietary trials</keyword>
  <keyword>Canadian Network</keyword>
  <keyword>knowledge synthesis and translation</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

